Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Industry By The Forecast Year 2029?
The ribonucleic acid (RNA) therapy clinical trials market size has demonstrated robust expansion over recent years. This market is set to increase from $2.57 billion in 2024 to $2.70 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.0%. The historical development in this sector can be attributed to a rising need for innovative treatments, the growing efficacy of mRNA vaccines, increased research investment, heightened clinical trial endeavors, and a greater demand for comparative genomics.
The ribonucleic acid (RNA) therapy clinical trials market size is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach a valuation of $3.25 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 4.8%. Several factors are contributing to this growth during the forecast period, including the rising prevalence of rare diseases, an increase in regulatory approvals, heightened investment in clinical research, greater patient participation, and an intensified focus on personalized medicine. Key trends expected throughout this period encompass advancements in RNA delivery systems, progress in biomarker-driven trial designs, the integration of artificial intelligence in trial design, the application of technology in decentralized clinical trials, and ongoing developments in regulatory fast-track pathways.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
Which Drivers Are Supporting Growth Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (RNA) therapy clinical trials market is anticipated to expand in the future due to the escalating problem of infectious diseases. These illnesses are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and undermine health. A primary contributor to the rise in infectious diseases is increased global travel, which facilitates the swift dissemination of pathogens across various regions and populations. Ribonucleic acid (RNA) therapy clinical trials assist in addressing infectious diseases by enabling the development and assessment of targeted treatments that can quickly adapt to emerging pathogens. For instance, in April 2025, a report from the Minnesota Department of Health, a US-based state agency, revealed that in 2024, the percentage of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17%. Therefore, the increasing prevalence of infectious diseases is a key factor driving the growth of the ribonucleic acid (RNA) therapy clinical trials market.
What Are The Emerging Segments Gaining Attention In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
What Are The Major Trends Driving The Growth Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Leading firms within the ribonucleic acid (RNA) therapy clinical trials market are concentrating on creating novel therapies, like RNA-based antisense oligonucleotide therapy clinical trials, designed to precisely target genetic sequences, adjust gene expression, and provide highly accurate treatments for genetic and uncommon diseases. Specifically, an RNA-based antisense oligonucleotide therapy clinical trial is defined as a study exploring the application of short synthetic RNA strands that attach to particular messenger RNA targets, with the goal of regulating gene expression and addressing genetic disorders. As an illustration, Sepul Bio, a biotechnology company headquartered in France, commenced the LUNA Phase 2b clinical trial in December 2024. This trial aims to assess ultevursen, an RNA-based antisense oligonucleotide therapy developed to target mutations within exon 13 of the USH2A gene, responsible for causing retinitis pigmentosa (RP) and Usher syndrome type 2a. This particular study, lasting two years and employing a double-masked, randomized, sham-controlled design, is set to include 81 adults and children aged eight and above at various global locations. The therapy is designed for persons with RP or non-syndromic RP resulting from exon 13 mutations in USH2A, a condition identifiable through genetic testing. The LUNA trial proceeds after positive findings from prior Phase 1/2 studies, in which ultevursen demonstrated advantages in visual acuity, retinal sensitivity, and retinal structure.
Which Industry Leaders Are Driving Innovation Across The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Charles River Laboratories International Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market 2025, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Global Market Report 2025
Nucleic Acid Based Gene Therapy Global Market Report 2025
Ribonucleic Acid Rna Sequencing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model